Transformation to SCLC after treatment with the ALK inhibitor alectinib

Journal of Thoracic Oncology

Volumn 11, Issue 6, 2016, Pages e67-e72

  Fujita, Shiro ^a   Masago, Katsuhiro ^a   Katakami, Nobuyuki ^a   Yatabe, Yasushi ^b  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; BEVACIZUMAB; CD56 ANTIGEN; CISPLATIN; CRIZOTINIB; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER PROGNOSIS; CANCER RESISTANCE; CASE REPORT; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GALLSTONE; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE GUIDED BIOPSY; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; METASTASIS; MONOTHERAPY; NEEDLE BIOPSY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL CELL LUNG CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; CHEMICALLY INDUCED; DRUG EFFECTS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY;

ADENOCARCINOMA; AGED; CARBAZOLES; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; LUNG NEOPLASMS; PIPERIDINES; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; SMALL CELL LUNG CARCINOMA;

EID: 84979743384     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.12.105     Document Type: Article

References (16)

1. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385-2394.
2. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167-2177.
3. Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res. 2015;21:2227-2235.
4. Toyokawa G, Taguchi K, Ohba T, et al. First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component. J Thorac Oncol. 2012;7: e39-e41.
5. Toyokawa G, Takenoyama M, Taguchi K, et al. An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene. Lung Cancer. 2013;81:487-490.
6. Sequist LV, Waltman BA, Dias-Santagata D, et al. Geno-typic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3: 75ra26.
7. Zakowski MF, Ladanyi M, Kris MG. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med. 2006;355:213-215.
8. Norkowski E, Ghigna MR, Lacroix L, et al. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology. J Thorac Oncol. 2013;8:1265-1271.
9. Oser MG, Niederst MJ, Sequist LV, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16:e165-e172.
10. Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6:6377.
11. Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104-1110.
12. Helin K, Holm K, Niebuhr A, et al. Loss of the retino-blastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci USA. 1997;94: 6933-6938.
13. Meuwissen R, Linn SC, Linnoila RI, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell. 2003;4:181-189.
14. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011;19:679-690.
15. Nanjo S, Nakagawa T, Takeuchi S, et al. In vivo imaging models of bone and brain metastases and pleural carci-nomatosis with a novel human EML4-ALK lung cancer cell line. Cancer Sci. 2015;106:244-252.
16. Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560-562.